Summary
Definition
History and exam
Key diagnostic factors
- lesões escamosas maculopapulares eritematosas em formato de disco
- idade de 20 a 40 anos
- história de exposição à luz ultravioleta
- história de tabagismo
Other diagnostic factors
- ausência de prurido e/ou dor
- telangiectasia, hiperpigmentação e/ou hipopigmentação
- alopecia cicatricial permanente
- características sistêmicas (artrite, pleurite, pericardite, convulsões, psicose)
Risk factors
- idade de 20 a 40 anos
- exposição à luz ultravioleta
- tabagismo
- sexo feminino
- lesão cutânea inespecífica
Diagnostic investigations
1st investigations to order
- fatores antinucleares, ácido desoxirribonucleico (DNA) de fita dupla (ds)
- Hemograma completo
- Velocidade de hemossedimentação (VHS)
- ureia e eletrólitos
- urinálise
Investigations to consider
- biópsia de pele
Treatment algorithm
doença localizada/limitada não grave
doença localizada/limitada grave ou refratária; doença disseminada
Contributors
Authors
Meng May Chee, MBChB, MRCP
Consultant Rheumatologist
Wishaw General Hospital
Wishaw
UK
Disclosures
MMC declares that she has no competing interests.
Girish Gupta, MBChB, FRCP
Consultant Dermatologist
Lauriston Building
NHS Lothian
Edinburgh
UK
Disclosures
GG is an advisory board member of Almirall, Galderma, and Viatris. GG has also been reimbursed for consultancy work by Almirall, Galderma, and AbbVie, and has received honoraria from Almirall, Galderma, Viatris, and La Roche-Posay for giving lectures.
Acknowledgements
Dr Meng May Chee and Dr Girish Gupta would like to gratefully acknowledge Dr Rajan Madhok, the previous contributor to this topic.
Disclosures
RM declared holding shares in GSK to the value of less than £12,000.
Peer reviewers
Jeffrey P. Callen, MD
Professor of Medicine (Dermatology)
University of Louisville
Louisville
KY
Disclosures
JPC declares that he has no competing interests.
Mark Goodfield, MD
Consultant Dermatologist
Department of Dermatology
Leeds General Infirmary
Leeds
UK
Disclosures
MG declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
O'Kane D, McCourt C, Meggitt S, et al; British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. 2021 Dec;185(6):1112-23.Full text Abstract
Lu Q, Long H, Chow S, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021 Sep;123:102707. Abstract
Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017 Mar;31(3):389-404.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Lúpus eritematoso sistêmico (LES)
- Lúpus eritematoso cutâneo subagudo (LECS)
- Psoríase
More DifferentialsGuidelines
- Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases
- Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus
More GuidelinesFolhetos informativos para os pacientes
Psoríase: quais são as opções de tratamento?
Psoríase: o que é?
Mais Folhetos informativos para os pacientes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal